Notably, consistent with the results obtained from PDAC (48), matrix metalloproteinase-cleaved COL-I rather than intact COL-I promoted DDR1 activity in HCC tumor cells, suggesting that targeting the components of cleaved COL-I-DDR1 signaling may provide an alternative therapeutic strategy for anti-HCC (20, 48). Here, DDR1 is linked to neoplasm.